key: cord-1023463-17tmqtkx
authors: Ameri, Ali; Asadi, Masoomeh Frouz; Kamali, Manoochehr; Vatankhah, Majid; Ziaei, Ava; Safa, Omid; Mahmudi, Masoomeh; Fathalipour, Mohammad
title: Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial
date: 2021-03-08
journal: Trials
DOI: 10.1186/s13063-021-05162-3
sha: c4c55f3abfe4b8c405ea3e9ffd03727ee547c6d2
doc_id: 1023463
cord_uid: 17tmqtkx

OBJECTIVES: We investigate the effects of melatonin, compared to the usual therapeutic regimen on clinical symptoms and laboratory signs in severely ill patients with confirmed COVID-19 who are admitted to the Intensive Care Unit (ICU). TRIAL DESIGN: This is a single-center, open-label, randomized, clinical trial with a parallel-group design. This study is being conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran. PARTICIPANTS: All patients admitted to the ICU of Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria. Inclusion criteria 1. Age >20 years 2. Definitive diagnosis of COVID-19 based on RT-PCR or/and serological testing 3. Severe pneumonia and lung involvement in imaging 4. Signing informed consent Exclusion criteria 1. Underlying diseases, including convulsive disorders, chronic hepatic and renal diseases 2. Use of mechanical ventilation 3. History of known allergy to Melatonin 4. Pregnancy and breastfeeding INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education’s protocol, along with Melatonin soft gelatin capsule (Danna Pharmaceutical Company) at a dose of 5 mg twice a day for a period of seven days. Control group: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education’s protocol for a period of seven days. MAIN OUTCOMES: The primary outcomes are the recovery rate of clinical symptoms and checking arterial blood gas (ABG), C-reactive protein (C-RP), Ferritin, Lactate dehydrogenase (LDH) within seven days of randomization. The secondary outcomes are time to improvement of clinical and paraclinical features and length of stay in the ICU, need for mechanical ventilation, and mortality rate within seven days of randomization. RANDOMIZATION: Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 6 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms. BLINDING (MASKING): This is an open-label trial without blinding and placebo control. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 60 participants randomizes (30 patients allocated to the intervention group and 30 patients allocated to the control group). TRIAL STATUS: The protocol is Version 1.0, February 16, 2021. Recruitment began February 28, 2021, and is anticipated to be completed by July 31, 2021. TRIAL REGISTRATION: The trial protocol has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is “IRCT20200506047323N7”. The registration date was February 16, 2021. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05162-3.

‫مالتونین‬ ( N - ‫استیل‬ - 5 - ‫متیوکسی‬ ‫تریپتامین‬ ) ‫یک‬ ‫مولکول‬ ‫فعال‬ ‫زیستی‬ ‫با‬ ‫مجموعه‬ ‫ای‬ ‫از‬ ‫خواص‬ ‫تقویت‬ ‫کننده‬ ‫سالمتی‬ ‫است‬ . ‫مالتونین‬ ‫با‬ ‫موفقیت‬ ‫در‬ ‫درمان‬ ‫اختالالت‬ ‫خواب‬ ، ‫دلیریوم‬ ، ‫آترواسکلروز‬ ، ‫بیماری‬ ‫تنفسی‬ ‫و‬ ‫عفونت‬ ‫های‬ ‫ویروسی‬ ‫مورد‬ ‫استفاده‬ ‫قرار‬ ‫گرفته‬ ‫است‬ [ 10 .] ‫تحقیقات‬ ‫قبلی‬ ‫اثرات‬ ‫مثبت‬ ‫مالتونین‬ ‫را‬ ‫در‬ ‫کاهش‬ ‫استرس‬ ‫حاد‬ ‫تنفسی‬ ‫ناشی‬ ‫از‬ ‫ویروس‬ ، ‫باکتریها‬ ، ‫پرتودرمانی‬ ‫و‬ ‫غیره‬ ‫را‬ ‫مستند‬ ‫کرده‬ ‫است‬ [ 11 - 13 .] ‫در‬ ‫شرایط‬ ‫مزمن‬ ‫مانند‬ ‫دیابت‬ ‫و‬ ‫مولتیپل‬ ‫اسکلروز‬ ‫مصرف‬ ‫مالتونین‬ ‫به‬ ‫ترتیب‬ ‫به‬ ‫مدت‬ 8 ‫هفته‬ ‫و‬ 6 ‫ماه‬ ‫به‬ ‫طور‬ ‫قابل‬ ‫توجهی‬ ‫سطح‬ ‫سرمی‬ TNF-α ، IL-6 ، IL-1β ‫و‬ CRP ‫را‬ ‫کاهش‬ ‫داده‬ ‫است‬ [ 14 , 15 .] ‫در‬ ‫شرایط‬ ‫حاد‬ ‫مانند‬ ‫استرس‬ ‫جراحی‬ ، ‫خونرسانی‬ ‫مجدد‬ ‫مغز‬ ‫و‬ ‫خونرسانی‬ ‫مجدد‬ ‫شریان‬ ‫کرونر‬ ‫استفاده‬ ‫روزانه‬ ‫از‬ ‫داروی‬ ‫خوراکی‬ ‫مالتونین‬ 10 mg / d ، 6mg / d ‫و‬ 5 mg / d ‫به‬ ‫ترتیب‬ ‫به‬ ‫طور‬ ‫قابل‬ ‫توجهی‬ ‫سطح‬ ‫سرمی‬ ‫سیتوکین‬ ‫های‬ ‫التهابی‬ ‫را‬ ‫کاهش‬ ‫می‬ ‫دهد‬ [ 16 - 18 .] ‫همانطور‬ ‫که‬ ً ‫قبال‬ ‫مورد‬ ‫بررسی‬ ‫قرار‬ ‫گرفت‬ ، ‫استفاده‬ ‫کوتاه‬ ‫مدت‬ ‫از‬ ‫مالتونین‬ ‫بی‬ ‫خطر‬ ‫است‬ ، ‫حتی‬ ‫در‬ ‫موارد‬ ‫مصرف‬ 7 ‫زیاد‬ ، ‫و‬ ‫عوارض‬ ‫جانبی‬ ‫گزارش‬ ‫شده‬ ‫محدود‬ ‫به‬ ‫سرگیجه‬ ، ‫سردرد‬ ، ‫حالت‬ ‫تهوع‬ ‫و‬ ‫خواب‬ ‫آلودگی‬ ‫هستند‬ . ‫به‬ ‫طور‬ ‫کلی‬ ‫ایمنی‬ ‫مالتونین‬ ‫در‬ ‫انسان‬ ‫بسیار‬ ‫باال‬ ‫است‬ [ 19 .] ‫در‬ ‫آزمایشات‬ ‫بالینی‬ ، ‫دوزهای‬ 3 ‫میلی‬ ‫گرم‬ ، 6 ‫میلی‬ ‫گرم‬ ‫و‬ 10 ‫میلی‬ ‫گرم‬ ‫خوراکی‬ ‫مالتونین‬ ‫خوراکی‬ ‫توسط‬ ‫بیماران‬ ‫در‬ ‫بخش‬ ‫مراقبت‬ ‫های‬ ‫ویژه‬ ، ‫در‬ ‫مقایسه‬ ‫با‬ ‫دارونما‬ ، ‫ایمنی‬ ‫رضایت‬ ‫بخش‬ ‫نشان‬ ‫داد‬ [ 9 .] ‫همچنین‬ ، ‫حتی‬ ‫وقتی‬ ‫مالتونین‬ ‫به‬ ‫مدت‬ ‫دو‬ ‫ماه‬ ‫به‬ ‫میزان‬ 1 ‫گرم‬ ‫در‬ ‫روز‬ ‫به‬ ‫انسان‬ ‫تجویز‬ ‫شد‬ ، ‫هیچ‬ ‫گزارش‬ ‫نامطلوبی‬ ‫از‬ ‫درمان‬ ‫گزارش‬ ‫نشده‬ ‫است‬ [ 20 .] ‫سرانجام‬ ، ‫هیچ‬ ‫عارضه‬ ‫جانبی‬ ‫پس‬ ‫از‬ ‫استفاده‬ ‫از‬ ‫مالتونین‬ ‫در‬ ‫مطالعات‬ ‫حیوانی‬ ALI / ARDS ‫ثبت‬ ‫نشده‬ ‫است‬ [ 9 .] ‫به‬ ‫همین‬ ‫ترتیب‬ ‫و‬ ‫با‬ ‫توجه‬ ‫به‬ ‫عدم‬ ‫وجود‬ ‫یک‬ ‫کارآزمایی‬ ‫بالینی‬ ‫در‬ ‫مورد‬ ‫تأثیر‬ ‫مالتونین‬ ‫بر‬ ‫بیماران‬ covid-19 ، ‫تصمیم‬ ‫به‬ ‫اجرای‬ ‫این‬ ‫کارآزمایی‬ ‫در‬ ‫بیمارستان‬ ‫شهید‬ ‫محمدی‬ ‫بندرعباس،‬ ‫هرمزگان،‬ ‫ایران‬ ‫گرفتیم‬ . 8 ‫متون‬ ‫بررسی‬ ‫معمول‬ ‫تظاهرات‬ COVID-19 ‫میالژی‬ ، ‫چشایی‬ ‫در‬ ‫اختالل‬ ‫و‬ ‫بو‬ ، ‫اشتهایی‬ ‫بی‬ ، ‫خستگی‬ ، ‫خشک‬ ‫سرفه‬ ، ‫تب‬ ‫شامل‬ ‫تظاهرات‬ ‫و‬ ‫گلودرد‬ ، ‫اسهال‬ ، ‫تهوع‬ ‫حالت‬ ، ‫سردرد‬ ، ‫بینی‬IL-1β ، IL-2 ، IL-6 ، IL-8 ‫را‬ ‫نشان‬ ‫می‬ ‫دهند‬ ، ‫هر‬ ‫دو‬ IFN-α / β ، TNF ‫کموکاین‬ ‫موتیف‬ ، 3 (CCL3) ، CCL5 ، CCL2 ‫و‬ IP-

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Emergence of novel coronavirus and progress toward treatment and vaccine

SARS-CoV-2 and COVID-19: The most important research questions

COVID-19: immunopathology and its implications for therapy

Clinical features of patients infected with 2019 novel coronavirus in

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology

COVID-19: Melatonin as a potential adjuvant treatment

Melatonin for the promotion of sleep in adults in the intensive care unit

Treatment of Ebola and other infectious diseases: melatonin "goes viral

Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 Axis. Oxidative medicine and cellular longevity

Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury

Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice

The effects of melatonin supplementation in adjunct with non-surgical periodontal therapy on periodontal status, serum melatonin and inflammatory markers in type

diabetes mellitus patients with chronic periodontitis: a double-blind, placebo-controlled trial

Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Archives of medical research

The protective effect of melatonin on brain ischemia and reperfusion in rats and humans: In vivo assessment and a randomized controlled trial

Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebocontrolled trial. medicine

Utility of melatonin to treat surgical stress after major vascular surgery-a safety study

The safety of melatonin in humans

The effects of oral melatonin on skin color and on the release of pituitary hormones

Early Insights into Immune Responses during COVID-19

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. The Journal of infectious diseases

Chemokine up-regulation in sars-coronavirus-infected, monocytederived human dendritic cells

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment

Protective effects of melatonin in mice infected with encephalitis viruses. Archives of virology

Anti-inflammatory effects of melatonin in a rat model of caeruleininduced acute pancreatitis

Melatonin: new insights on its therapeutic properties in diabetic complications

Internal clock and the surgical ICU patient

Determination of Melatonin Deprivation Impact on Sepsis With Acute Phase Reactants

Role of melatonin in attenuation of haemodynamic responses to laryngoscopy and intubation

The use of high-dose melatonin in liver resection is safe: first clinical experience

Premedication effect of melatonin on propofol induction dose for anesthesia, anxiety, orientation and sedation after abdominal surgery: a double-blinded randomized trial

Pharmacokinetics of high-dose intravenous melatonin in humans

Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis

Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model